ValuentumAd

Official PayPal Seal













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Oct 28, 2015
We’ll Be Looking to Add to B-Dubs Sometime after the Drop
Buffalo Wild Wings disappoints, but guides to 2016 earnings growth of 20%+. We may have an opportunity to ease closer to a full position in shares (~5%) in the Best Ideas Newsletter portfolio…but not yet. We’ll be sitting on our less-than-1% weighting until the dust settles.
Oct 28, 2015
Around the Horn in Biotech/Pharma: 3Q Earnings Review
Abbott, Biogen, Bristol-Myers, Eli Lilly, Gilead, GlaxoSmithKline, Merck, Pfizer…
Oct 27, 2015
Apple Owns the “Sixth Source” of an Economic Moat
Apple delivers yet again, beating fiscal fourth-quarter expectations by a large margin.
Oct 27, 2015
A 10%+ Cost of Capital for Midstream Equities Is Reality
Kinder Morgan floated equity capital at a cost of ~12%. The implications are far-reaching.
Oct 27, 2015
Are You Still Trying to Catch Lightning with American Capital Agency?
It may be time to stop reading some of the “bull-ishness” on other websites?
Oct 27, 2015
Explaining the New Page 2 of the Dividend Report
We've added another page to the dividend-report companion to the full 16-page report of each company. Let's walk through some of the new report specifics in the context of Best Ideas Newsletter portfolio holding Visa.
Oct 27, 2015
The Dividend Cushion Ratio Measures the Magnitude of Potential Dividend Increases
The Dividend Cushion ratio not only showcases companies at risk of a dividend cut, but it also reveals the magnitude of potential dividend increases to come.
Oct 27, 2015
Coach Back on Track?
The struggling women’s handbag maker has seen better days, but has it finally turned the corner?
Oct 27, 2015
BABA Bounces Big! GMV Growth Solid, Monetization Rate Better
The Chinese e-commerce giant is back on track, and we’re mighty pleased. We continue to believe shares are undervalued by a large margin. If you haven’t viewed our 16-page report on the company to see by how much, please do so.
Oct 26, 2015
If It Happened to AbbVie, Could It Also Happen to Gilead?
Recent news concerning AbbVie’s hepatitis C drugs caused a severe decline in the company’s share price. Could such an event happen to Gilead?


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.